$24.00
Manufacturer: Cyprus,
Purpose: Lower blood pressure by increasing urine output for hypertension treatment.
Description
Ramimed Combi (ramipril, hydrochlorothiazide) tablets 5 mg/25 mg. №30
Ingredients
Each tablet contains:
- Ramipril 5 mg
- Hydrochlorothiazide 25 mg
Dosage
The recommended dosage is one tablet daily.
It is important to follow the instructions provided by your healthcare provider.
Indications
Ramimed Combi tablets are indicated for the treatment of hypertension in patients where combination therapy is appropriate.
Contraindications
Do not take Ramimed Combi tablets if:
- You are allergic to ramipril, hydrochlorothiazide, or any other ingredients in the product.
- You have a history of angioedema related to previous treatment with ACE inhibitors.
Directions
Take one tablet orally with a full glass of water.
It can be taken with or without food, but it is important to be consistent.
Scientific Evidence
Ramimed Combi combines the effects of ramipril, an ACE inhibitor, and hydrochlorothiazide, a diuretic.
Studies have shown that this combination is effective in lowering blood pressure and reducing the risk of cardiovascular events.
Research published in the Journal of Hypertension demonstrated the superior efficacy of ramipril and hydrochlorothiazide combination therapy compared to monotherapy in hypertensive patients.
Additional Information
Ramimed Combi should be used under the supervision of a healthcare provider.
Regular monitoring of blood pressure and kidney function is essential during treatment with this medication.
Pharmacological Effects: Ramipril works by inhibiting the angiotensin-converting enzyme, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide acts on the kidneys to increase the excretion of sodium and water, thus reducing blood volume and lowering blood pressure.
Clinical Trials: A randomized controlled trial published in the New England Journal of Medicine showed that the combination of ramipril and hydrochlorothiazide significantly reduced the incidence of stroke and myocardial infarction in high-risk patients compared to placebo.
Recent Reviews